Skip to content
Home/Companies/MedTech/Regenity Biosciences
Regenity Biosciences

Regenity Biosciences

MedTech·United States·Active·New
Entry
2026
Hold
New
Status
Active

Who owns Regenity Biosciences?

Regenity Biosciences is an American MedTech company, currently owned by Cinven since 2026.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Cinven
Investor
Cinven
Cinven Fund VIII · 2024 · Buyout

Key facts

HQUnited States
SectorMedTech
Websiteregenity.com

More from Cinven Fund VIII

Other portfolio companies in the same fund.

Salsify
Active
SaaSUS· 2026
Artefact
Artefact
Active
Business ServicesUK· 2025
Flint Global
Flint Global
Active
Business ServicesUK· 2025
Grant Thornton
Grant Thornton
Active
FinancialsUK· 2025
Nutrisens
Nutrisens
Active
HealthcareFrance· 2025
Objectway
Active
FintechUK· 2025

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Regenity Biosciences?

Regenity Biosciences is currently owned by Cinven, through Cinven Fund VIII, since 2026.

When did Cinven acquire Regenity Biosciences?

Cinven acquired Regenity Biosciences in 2026.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue